Table 2 Regression analyses of the association between adoption of CDC HIV pre-test counseling guidelines and availability of HCV testing (HCV testing vs. No HCV testing)
No HCV testing options offereda | HCV testing offered | P-value | Unadjusted Odds Ratio (95 % CI)b | Adjusted Odds Ratio (95 % CI)b | |
|---|---|---|---|---|---|
State-level legislation enables eliminating HIV pretest counseling requirement | <0.01 | ||||
No | 44 (24.7) | 134 (75.3) | 1 | 1 | |
Yes | 26 (12.7) | 179 (87.3) | 2.26 (1.32, 3.86) | 0.87 (0.19, 4.07) | |
Prevalence of injection drug users | 0.07 | ||||
< 25 % | 33 (24.8) | 100 (75.2) | 1 | 1 | |
25-74 % | 24 (14.9) | 137 (85.1) | 1.88 (1.05, 3.39) | 2.21 (0.97, 5.04) | |
≥ 75 % | 13 (15.5) | 71 (84.5) | 1.80 (0.89, 3.67) | 1.44 (0.51, 4.11) | |
African-American patients | 0.05 | ||||
< 10 % | 24 (13.9) | 148 (86.1) | 1 | 1 | |
≥ 10 % | 46 (21.8) | 165 (78.2) | 0.58 (0.34, 0.99) | 0.85 (0.37, 1.94) | |
Hispanic patients | 0.17 | ||||
< 10 % | 41 (20.9) | 155 (79.1) | 1 | 1 | |
≥ 10 % | 29 (15.5) | 158 (84.5) | 1.44 (0.85, 2.44) | 1.27 (0.54, 2.97) | |
Revenue from federal government | 0.85 | ||||
None | 50 (18.5) | 220 (81.5) | 1 | 1 | |
≥ 1 % | 20 (17.7) | 93 (82.3) | 1.06 (0.60, 1.87) | 1.15 (0.53, 2.49) | |
Revenue from private insurance | 0.18 | ||||
None | 35 (16.0) | 184 (84.0) | 1 | 1 | |
≥ 1 % | 35 (21.3) | 129 (78.7) | 0.70 (0.42, 1.18) | 1.11 (0.51, 2.43) | |
Human resources | |||||
Log Staff-to-patient ratio, mean (SD) | -3.56 (0.76) | -3.31 (0.72) | 0.01 | 1.53 (1.09, 2.16) | 1.30 (0.82, 2.06) |
CARF accreditation | 0.01 | ||||
No | 45 (23.2) | 149 (76.8) | 1 | 1 | |
Yes | 25 (13.2) | 164 (86.8 | 1.98 (1.16, 3.39) | 2.23 (0.98, 5.08) | |
Ownership | 0.78 | ||||
Private not-for-profit | 36 (19.6) | 148 (80.4) | 1 | 1 | |
Private for profit | 24 (16.6) | 121 (83.4) | 1.22 (0.69, 2.17) | 0.91 (0.40, 2.08) | |
Public | 10 (18.5) | 44 (81.5) | 1.07 (0.49, 2.33) | 0.97 (0.33, 2.80) | |
Hospital affiliation | 0.09 | ||||
No | 64 (19.7) | 261 (80.3) | 1 | 1 | |
Yes | 6 (10.3) | 52 (89.7) | 2.12 (0.87, 5.17) | 3.39 (1.13, 10.2) | |
Methods of treatment | <0.01 | ||||
Methadone only | 45 (20.7) | 172 (79.3) | 1 | 1 | |
Buprenorphine only | 22 (23.2) | 73 (76.8) | 0.87 (0.49, 1.55) | 1.55 (0.62, 3.88) | |
Methadone + Buprenorphine | 3 (4.2) | 68 (95.8) | 5.93 (1.78, 19.8) | 6.63 (1.61, 27.4) | |
Time | <0.01 | ||||
2005 | 50 (26.7) | 137 (73.3) | 1 | 1 | |
2011 | 20 (10.2) | 176 (89.8) | 3.21 (1.82, 5.65) | 3.20 (0.87, 11.7) | |
N | 70 (18.3) | 313 (81.7) | 383 | 292c | |